* Drug fails in one trial, succeeds in another
* To continue another follow-on trial
* Sucampo shares up 8 pct
Sucampo Pharmaceuticals Inc (SCMP.O) and a unit of Japan's Takeda Pharmaceutical (4502.T) said two identical late-stage trials of their experimental drug for opioid-induced bowel dysfunction (OBD) showed mixed results, with one study meeting the main goal and the other failing.
The study named OBD0631 met the main goal of showing a statistically significant change in the frequency of spontaneous bowel movements at the eighth week of treatment when the drug, lubiprostone, was compared to a dummy drug.
However, another trial, named OBD0632, failed to achieve the same goal.
Sucampo will continue another follow-on safety study in 445 patients who would receive one 24-mcg gel capsule of lubiprostone twice a day for nine months. It expects data from this study in late 2009.
If the follow-on study is successful, Sucampo expects to submit the data to U.S. health regulators in 2010.
Sucampo shares were up 8 percent at $7.00 in trading after the bell. They closed at $6.50 Tuesday on Nasdaq.
No comments:
Post a Comment